Table 2 TEAEs occurring in ≥ 5% participants overall
From: Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia
| Â | Double-blind, single-ascending-dose healthy volunteers | Open-label | |||||||
|---|---|---|---|---|---|---|---|---|---|
|  |  | Latozinemab dose level |  |  | aFTD-GRN 60 mg/kg (N = 6) | ||||
MedDRA preferred term n (%) [E] | Pooled placebo (n = 12) | 2 mg/kg (n = 7) | 6 mg/kg (n = 6) | 15 mg/kg (n = 6) | 30 mg/kg (n = 6) | 60 mg/kg (n = 13) | Total AL001 (n = 38) | Total (N = 50) | |
Post–lumbar puncture syndrome | 2 (16.7) | 0 | 0 | 1 (16.7) | 3 (50.0) | 3 (23.1) | 7 (18.4) | 9 (18.0) | 1 (16.7) |
Puncture site pain | 2 (16.7) | 0 | 0 | 0 | 0 | 3 (23.1) | 3 (7.9) | 5 (10.0) | 0 |
Headache | 0 | 0 | 0 | 0 | 3 (50.0) | 1 (7.7) | 4 (10.5) | 4 (8.0) | 0 |
Anemia | 1 (8.3) | 0 | 0 | 1 (16.7) | 1 (16.7) | 0 | 2 (5.3) | 3 (6.0) | 0 |
Vomiting | 0 | 1 (14.3) | 0 | 0 | 1 (16.7) | 1 (7.7) | 3 (7.9) | 3 (6.0) | 0 |